Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.

Tempus AI, Inc. (TEM) Stock Price & Market Analysis
TEM · NASDAQ · Medical - Healthcare Information Services
$69.26
▼ -$6.64(-8.74%)11:46 AM ET - vs previous closeQuote as of Nov 13, 2026, 11:46 AM EST
NASDAQ regular-session quote as of Nov 13, 2026, 11:46 AM EST.
Long-term rangesAvailable historyHide
Historical range: 2024-06-14–2026-11-13. Earlier trading may not be included.
Loading price chart…
Data dates
PriceDelayedLast traded
FundamentalsLast checked
AnalystLast checked
NewsLatest item
Reported fundamentals
TEM financial overview
Annual revenue
USD 1.27B
Sales for the fiscal year ended Dec 31, 2025. This is not trailing twelve-month revenue.
Revenue change
+83.4%
Change versus the fiscal year ended Dec 31, 2024.
Net profit margin
-19.3%
Net income divided by revenue for the fiscal year ended Dec 31, 2025. This is not the trailing margin.
These reported results describe the business’s recent scale and profitability. Compare cash generation and valuation before forming an investment view; historical growth is not a forecast.
Company · ProfileAbout Tempus AI, Inc. (TEM)Sector, leadership, and how Tempus AI, Inc. earns its revenue.Healthcare
Tempus AI, Inc.
NASDAQ · TEM · US
Company overview as of Nov 13, 2026.
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- Headquarters
- Chicago, IL, United States
- Country
- US
- Employees
- 3,800
- CEO
- Mr. Eric P. Lefkofsky J.D.
- Exchange
- NASDAQ
Business model & operating resultsExplore business exposure, reported operating measures and the figures behind growth and profitability claims.
Narrative versus numbers
Demand is expanding
Supporting observation: 23.1%
Year-over-year growth in the latest quarter. This differs from the fiscal-year revenue change shown above. · Source timestamp: Sep 30, 2026
Growth produces accounting profit
Contradicting observation: -12.5%
Net margin; the source did not supply a reporting period. Do not compare this reading with the quarterly or fiscal-year figures above. A positive margin does not establish cash generation. · Source timestamp: Nov 13, 2026, 11:46 AM EST
The business generates cash after investment
Contradicting observation: USD -122K
Latest free cash flow from the statement feed. It is not a forecast and may cover a different period from the fiscal-year figures above. · Source timestamp: Sep 30, 2026
These are explicit tests of individual claims, not an overall bull/bear rating. Demand growth can coexist with valuation, concentration and financing risk.
Operating measures
- Revenue
- $411.54Mquarter ended Sep 30, 2026
- Operating margin
- -13.8%quarter ended Sep 30, 2026
- EPS
- -$0.08quarter ended Sep 30, 2026
- Capital expenditure
- $9.34Mquarter ended Sep 30, 2026
- Free cash flow
- -$122,000.00quarter ended Sep 30, 2026
- Free cash flow margin
- -0.0%quarter ended Sep 30, 2026
- Revenue growth year over year
- 23.1%quarter ended Sep 30, 2026
Competitors & comparisonsCompare industry peers, reporting periods and related funds. Business mix and valuation bases may differ.
Valuation & fund comparisonsExplore dated peer valuations, growth comparisons and related funds.
Governance & sustainability
Regular session
Regular hours: 9:30 AM–4:00 PM America/New_York
Next open: 2026-11-16 · 9:30 AM America/New_York
Exchange calendar includes scheduled holidays and early closes. Extended-session prices appear separately only when supplied by the quote source.
Shortcuts
With research tools focused: / search · W watchlist · C compare · F financials · E earnings · N news · T technicals · Esc close